FDA Strikes Hard at Coronavirus Outbreak with New PolicyFDA Strikes Hard at Coronavirus Outbreak with New Policy

The federal agency will allow laboratories to begin and use the diagnostics for the coronavirus before FDA has completed a review of their Emergency Use Authorization requests.

Omar Ford

March 2, 2020

2 Min Read
MDDI logo in a gray background | MDDI

FDA is upping its response to address the novel coronavirus outbreak. The policy is aimed at laboratories seeking to develop diagnostic tests for the coronavirus.

The policy allows laboratories to develop and begin to use the diagnostics before FDA has completed a review of their Emergency Use Authorization (EUA) requests.

"We believe this policy strikes the right balance during this public health emergency," said FDA Commissioner Stephen M. Hahn, M.D. "We will continue to help to ensure sound science prior to clinical testing and follow-up with the critical independent review from FDA, while quickly expanding testing capabilities in the U.S. We are not changing our standards for issuing Emergency Use Authorizations. This action today reflects our public health commitment to addressing critical public health needs and rapidly responding and adapting to this dynamic and evolving situation."

Co-Diagnostics is an in vitro diagnostics firm that has been out in the forefront during the outbreak. Last month the Salt Lake City, UT-based company received CE mark Logix Smart Coronavirus COVID-19 Test.

In response to FDA’s new policy, the company said it is in discussions with certain qualified CLIA laboratories who can use COVID-19 tests built on Co-Diagnostics' platform technology in their EUA submissions with FDA. Co-Diagnostics said once the labs have completed the process required for the EUA submission, it is expected that they would purchase the company’s reagents for use in their COVID-19 diagnostics, as permitted by FDA.

In a release Dwight Egan, CEO of Co-Diagnostics, commented, “We believe this change will allow the diagnostics industry to respond to the developing situation much more rapidly and effectively, and we applaud the FDA for taking such aggressive action to address the coronavirus outbreak.”

In late January, FDA laid out its strategy to handle any potential coronavirus outbreaks. Early last month, FDA granted EUA for the Centers for Disease Control and Prevention’s Coronavirus detection test. Up until then, the Prevention’s 2019-nCoV Real-Time RT-PCR Diagnostic Panel has only been used at CDC laboratories.

FDA’s new policy comes at a time when there are 89,856 cases worldwide. About 3,069 have succumbed to the virus and 45,636 have recovered, according  to Worldometer. In the U.S, there have been two reported deaths.

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like